文献速递肝病消化道出血

利福昔明减少肝移植等待名单患者自发性细菌性腹膜炎、静脉曲张出血及全因入院

Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list.
PubMed 文献 · Aliment Pharmacol Ther · 2019-06-06

利福昔明组全因入院、自发性细菌性腹膜炎及静脉曲张出血减少,平均住院日9天(95%CI 6-12) vs 14天(95%CI 7-21),多因素回归显示利福昔明与再入院平均天数增加(校正效应估计71天,95%CI 3-140)及等待名单优先需求降低(OR 0.29;95%CI 0.89-0.93)独立相关。

要点

  • 利福昔明组全因入院、自发性细菌性腹膜炎及静脉曲张出血减少。
  • 平均住院日利福昔明组9天(95%CI 6-12) vs 未使用组14天(95%CI 7-21)。
  • 利福昔明与再入院平均天数增加独立相关(校正效应估计71天,95%CI 3-140)。

核心结论

  • 肝移植等待名单中因肝性脑病使用利福昔明的患者,结局改善,自发性细菌性腹膜炎、腹水及静脉曲张出血相关入院显著减少。

主要发现

  • 利福昔明组全因入院、自发性细菌性腹膜炎及静脉曲张出血减少。
  • 平均住院日利福昔明组9天(95%CI 6-12) vs 未使用组14天(95%CI 7-21)。
  • 多因素回归显示利福昔明与再入院平均天数增加独立相关(校正效应估计71天,95%CI 3-140)。
  • 利福昔明与等待名单优先需求降低独立相关(OR 0.29;95%CI 0.89-0.93)。
  • 两组同时使用乳果糖无显著差异,中位MELD评分相似(利福昔明组15[14-16] vs 未使用组16[14-18])。

临床怎么用

  • 对于肝移植等待名单中因肝性脑病考虑治疗的患者,利福昔明使用与自发性细菌性腹膜炎、静脉曲张出血及全因入院减少相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rifaximin reduces the risk of overt hepatic encephalopathy (HE) and is associated with significant reductions in hospitalisations and 30-day readmissions. AIM: To examine the outcomes of patients listed for liver transplantation with a diagnosis of HE on rifaximin compared to those naïve to the drug. METHODS: Patient records of those listed for liver transplantation over a 2-year period were retrospectively reviewed. Patients were included if they had at least two episodes of overt HE resulting in hospitalisation or were encephalopathic at the time of assessment. RESULTS: Of the 622 patients listed for transplantation, 101 had HE. Sixty-six patients were treated with rifaximin and 35 were naïve at listing. The use of concurrent lactulose was not significantly different between groups. Median MELD score was similar (15 [14-16)] rifaximin-treated and 16 [14-18] rifaximin-naïve). Patients on the waiting list treated with rifaximin had reduced all-cause admissions, episodes of spontaneous bacterial peritonitis and variceal bleeding. Mean length of stay was 9 days (95% CI 6-12) in the rifaximin-treated group vs 14 (95% CI 7-21) in the rifaximin-naïve group. Multivariate regression analysis demonstrated that rifaximin was independently associated with an increase in average days to readmission (adjusted effect estimate 71, 95% CI 3-140 days) and reduced likelihood of requirement for prioritisation on the waiting list (odds ratio 0.29; 95% CI 0.89-0.93). CONCLUSION: Rifaximin prescribed for HE in patients listed for liver transplantation improved outcomes with significant reduction in admissions related to spontaneous bacterial peritonitis, ascites and variceal bleeding.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Salehi S, Tranah TH, Lim S, et al. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther. 2019. PMID: 31169941. doi:10.1111/apt.15326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。